|Immunodiagnostic Systems Hldgs
||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Immunodiagnostic Systems Share Discussion Threads
Showing 851 to 873 of 875 messages
|Yes, very welcome finish to the week. My concern is that the share price is getting ahead of itself and results may disappoint in comparison. This may lead to a pull back at some point, though I expect it would be short lived based on the recent price action.|
|Price looking perky here.|
|Interesting to see that a sovereign wealth fund is increasing its stake: one wouldn't have thought IDH was big enough to warrant the attention of a fund worth 7.5 trillion NOK!|
|You got it exactly wrong, but thanks for making a market.|
|The chart says it all
This stock is in trouble
free stock charts from uk.advfn.com
Recent profit warning suggests blue line to be tested once more|
|Any news that I'm unaware of?|
|Larger partner could strip out opex, and run the existing business off for cash. Cash would also significantly reduce implied ev. Will be on the radar for the big cash rich players. Could be a sizeable premium.|
|value trap. avoid|
|It just seems to get worse and worse. This will become an interesting recovery play in time.If/when it gets to 80p I might buy a few.|
|Management have been asleep at the wheel.Circa 85p cash and high gross margin.Takeout candidate.|
|£42m market cap, £26m cash, £35m net tangible equity, and a (albeit declining) business making £39m turnover at 60%+ gross margins.Quite interesting.|
|The directors office revolving door continues|
Immunodiagnostic Systems Holdings (IDH LN)
Full Year Results
Prelims in line – outlook remains challenging
FY15 was a difficult year and FY16 is unlikely to be any better. Our forecasts and Target Price remain under review, and we see little prospect of a rapid turnaround in the group’s fortunes. We retain our Sell recommendation.|
Don't hold myself but have an interest via ODX (whom are developing a product in collaboration with IDH).
They do seem to be struggling with net placement of machines. Not sure as to why they are getting returned: competition or business disappearing? Doesn't look like the geographic expansion plans are going well either.|
|Looks like significant warning on both sales and profits to me (imo etc)
Looks as though both singer and Cnaccord were right in call this a sell in March and April respectively
I suspect we may see further broker downgrades after today's statement.
BIG QUESTION: Why are sales down - Competitive activity ? Better competitive products ?
Thoughts - Knowledge ?
Declaration - Do not hold but been on watch list.|
|Is this a profit warning with sales below epectations?|
|modestly priced for such a great growth stock in recent times.
statement looked alright.|
|......or it may be the China angle?|
|I hold quite a few bought in stages from 245p onwards. The thing that intrigues me most is the China angle and also the net cash pile which keeps on growing.
At some stage, I hope, we should be rewarded with a special dividend.
I think the current drop over successive days may be a tree shake before results.|
|Your comments noted, UVA, thanks. I prefer to sit tight unless something is wrong. Also hold it's cousin,ODX, which is also doing quite well for me.|
|There is nothing wrong here.
Little pull back on no news.
valuation looks undemanding for this kind of a stock.|
|Can anyone comment in the fall in the share price which seems to correlate with the departure of Dr Wittek (non-exec) from the Board?
This is a negelected thread considering the useful increase in share price. I came in at 290 after the big drop - should I be exiting?|
|Investec has downgraded its recommendation on medical diagnostic product manufacturer Immunodiagnostic Systems [LON:IDH] to 'hold' from 'buy' after the company published an in-line set of preliminary results, believing the shares will pause for breath after the recent strong run.
The shares have increased in value by 40 per cent since the beginning of the year.
The City broker has increased its price target to 460 pence per share (up from 360 pence).
Separately, N+1 Singer has reaffirmed its 'buy' rating and 395 pence price target, while Canaccord Genuity has stuck with its 'hold' call leaving its price target unchanged at 404 pence per share.
At 10:09am: Immunodiagnostic Systems share price was unchanged at 447.5 pence.
(Courtesy of brokerforecasts.com)|